Shares of AmpliTech Group cratered 19.2% to $4.84 in after-hours trading on August 13 after Q2 results revealed a company growing fast on top but bleeding cash underneath. The quarter crystallizes a familiar small-cap dilemma: how long will investors fund heavy spending before profits materialize?
Revenue Hit a Record, but It's Still Not Enough to Reach the Finish Line. Q2 revenue of $8.07 million jumped 50.9% from Q1's $5.35 million, delivering on management's promise that the second quarter would be "definitely much higher." Q1 2026 itself was up 48.6% year-over-year, reaching $5.35 million. Yet the first-half total of roughly $13.4 million covers barely a quarter of the company's full-year target of at least $50 million for fiscal year 2026, representing approximately 100% year-over-year growth. That means AmpliTech must generate roughly $36.6 million in the final two quarters — a pace it has never demonstrated.
The Loss Doubled Because AmpliTech Is Spending to Build a Business That Doesn't Fully Exist Yet. Net loss widened to $3.09 million, more than double Q1's net loss of $1.52 million. Research-and-development spending on 5G radio equipment and specialized microwave chips (MMICs) is the main culprit. Gross profit improved 161.2% year-over-year, proving the products sell at healthier margins — Q1 gross margins improved significantly from 33% to 48%. But those margin gains are being swallowed by lab costs aimed at commercializing next-generation wireless gear.
Big Contracts Look Promising on Paper, but Execution Risk Is Real. AmpliTech confirmed production shipments under its $100 million letter of intent started in December 2025, and shipments under its $40 million LOI with a North American mobile network operator resumed early in Q1.
The company has a strong backlog of over $20 million in orders. However, letters of intent are non-binding, and management itself cited geopolitical tensions, logistics cost volatility, and supplier lead times as factors that could affect revenue timing.
A Buyback Signals Confidence, but Dilution Already Happened. In July, the board authorized a $10 million share repurchase program and terminated its at-the-market equity offering. That pivot is notable given AmpliTech has 22.95 million shares outstanding, a count that increased 86.22% in one year through prior capital raises. Whether buybacks can offset that dilution — and whether the company can afford them while still losing money — remains the central tension heading into the make-or-break second half.